Lupus Research Alliance Hails Approval of Aurinia s Lupkynis(TM) (voclosporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
News provided by
Share this article
Share this article
NEW YORK, Jan. 22, 2021 /PRNewswire/ The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals Lupkynis
TM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month.